Voyage of Measurable Residual Disease Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry
Indian Journal of Medical and Paediatric Oncology, ISSN: 0975-2129, Vol: 44, Issue: 5, Page: 515-524
2023
- 2Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures2
- Readers2
- Mentions1
- News Mentions1
- 1
Most Recent News
Recent Findings in Multiple Myeloma Described by a Researcher from Dr. B.R.A. Institute Rotary Cancer Hospital (Voyage of Measurable Residual Disease Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry)
2023 NOV 20 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Hematology Daily -- Researchers detail new data in multiple myeloma. According to
Review Description
Measurable residual disease (MRD) in multiple myeloma (MM) has emerged as one of the strongest and independent biomarkers to evaluate therapeutic response for the prediction of long-term treatment outcome. With the incorporation of MRD in response assessment criterion by International Myeloma Working Group, it has become the routine parameter to be assessed at various time points after therapy. Among various techniques to assess MRD, multiparametric flow cytometry (MFC)-based MRD estimation has evolved dramatically over the last two decades achieving sensitivity comparable to molecular methods. Next-generation flow cytometry with the incorporation of innovative tools in MRD detection including consortium-based guidelines for preanalytical and analytical factors led to the overall improvement in MFC-based MRD detection. However, flow cytometry assays suffer from inherent challenges ranging from procedural hemodilution to lack of harmonization and standardization across the centers.This review article outlines and summarizes the essential laboratory prerequisites for reproducible MRD analysis by flow cytometry. Furthermore, a brief account of the utility of MRD evaluation in clinical practice as predictor of response and long-term treatment outcome has also been discussed. Considering the evolution of MFC-based MRD over two decades from a scientific research tool to a routine clinical diagnostic assay, it needs to be explored further in studying complex phenomenon like clonal evolution, clonal switches, and identification of treatment refractory clones for guiding more effective therapies improving overall survival.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85178403692&origin=inward; http://dx.doi.org/10.1055/s-0043-1768176; http://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-1768176; https://dx.doi.org/10.1055/s-0043-1768176; https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0043-1768176
Georg Thieme Verlag KG
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know